Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243419 | 0.87 | CA2 (0.40) | CA2CA1CA7CA9CA12 | |
| SCHEMBL26497872 | 0.81 | TRPA1 (0.40) | NPC1CA2CA1CA9TSHR | |
| SCHEMBL9200717 | 0.80 | PLCG1 (0.46) | NPC1PLCG1CA2HTR2ATAAR1 | |
| SCHEMBL1138688 | 0.80 | PLCG1 (0.46) | NPC1PLCG1CA2HTR2ATAAR1 | |
| SCHEMBL925715 | 0.78 | KMT2A (0.50) | CA2TAAR1EGFRERBB2CYP2A6 | |
| SCHEMBL29221410 | 0.78 | CA2 (0.41) | CA2CA1CA9L3MBTL1 | |
| SCHEMBL2377606 | 0.77 | TAAR1 (0.46) | PLCG1CA2HTR2ATAAR1EGFR | |
| SCHEMBL2028261 | 0.76 | PLCG1 (0.43) | NPC1PLCG1CA2HTR2ATAAR1 | |
| SCHEMBL11069054 | 0.76 | CA2 (0.50) | CA2TAAR1EGFRCYP2A6TSHR | |
| SCHEMBL14536592 | 0.76 | ESR1 (0.46) | CA2TAAR1IDO1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4688741-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | Meta-Immune, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| CN-115515939-B | Novel phthalazine derivatives having activity of inhibiting exonucleotide pyrophosphatase-phosphodiesterase and their use | 谛希诺生物科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024249867-A1 | COMPOUNDS FOR TREATING FIBROTIC DISEASES | AM SCIENCES (KR) | 2024-12-05 | — | — | WO | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024179529-A1 | SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | GENENTECH, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-118359542-A | Polysubstituted pyrazole compound and preparation method and application thereof | 甫康（上海）健康科技有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-1997029092-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-08-14 | — | — | WO | disclosed |
| US-5656412-A | Energy-sensitive resist material and a process for device fabrication using an energy-sensitive resist material | LUCENT TECHNOLOGIES INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0731388-A2 | An energy-sensitive resist material and a process for device fabrication using an energy-sensitive resist material | AT&T Corp. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5473067-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1995-12-05 | — | — | US | disclosed |
| US-5424448-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0617038-A1 | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5344929-A | Preparation of carbonic anhydrase inhibitors | ALCON LABORATORIES, INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-4222937-A | Total synthesis of the utero-evacuant substance D,L-zoapatanol | ORTHO PHARMACEUTICAL CORP. (US) | 1980-09-16 | — | — | US | disclosed |
| US-4177194-A | Total synthesis of the utero-evacuant substance D,L-zoapatanol | ORTHO PHARMACEUTICAL CORPORATION (US) | 1979-12-04 | — | — | US | disclosed |
| US-3943157-A | Synthesis of codling moth attractant | ZOECON CORPORATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | NPC1 2558/4885PLCG1 2423/4885CA2 274/4885 |
| US-12071425-B2 | Phenoxy-pyridyl-pyrimidine compounds and methods of use | XBP1, ERN1, ESR2 | NPC1 1937/4885PLCG1 247/4885CA2 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.